Literature DB >> 16722815

Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus.

Mariele Briones1, Mandeep Bajaj.   

Abstract

Exenatide is a glucagon-like peptide 1 receptor agonist, which has recently received FDA approval in the US for the treatment of Type 2 diabetes. Exenatide is an incretin mimetic that improves glycaemic control in patients with diabetes through acute mechanisms, such as glucose-dependent stimulation of insulin secretion, suppression of inappropriate glucagon secretion and slowing of gastric emptying, as well as chronic mechanisms that include enhancement of beta-cell mass in rodent studies and weight loss and inhibition of food intake in humans. This article reviews the mechanisms of exenatide action, as well as its efficacy in the treatment of Type 2 diabetes.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16722815     DOI： 10.1517/14656566.7.8.1055

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN： 1465-6566            Impact factor:   3.889


  18 in total

1.  Acute effects of an oral supplement of (-)-epicatechin on postprandial fat and carbohydrate metabolism in normal and overweight subjects.

Authors:  Gabriela Gutiérrez-Salmeán; Pilar Ortiz-Vilchis; Claudia M Vacaseydel; Ivan Rubio-Gayosso; Eduardo Meaney; Francisco Villarreal; Israel Ramírez-Sánchez; Guillermo Ceballos
Journal:  Food Funct       Date:  2014-03       Impact factor: 5.396

Review 2.  Molecular imaging of β-cells: diabetes and beyond.

Authors:  Weijun Wei; Emily B Ehlerding; Xiaoli Lan; Quan-Yong Luo; Weibo Cai
Journal:  Adv Drug Deliv Rev       Date:  2018-07-03       Impact factor: 15.470

Review 3.  Selective tissue targeting of synthetic nucleic acid drugs.

Authors:  Punit P Seth; Michael Tanowitz; C Frank Bennett
Journal:  J Clin Invest       Date:  2019-01-28       Impact factor: 14.808

Review 4.  Dysregulation of glucose metabolism in HIV patients: epidemiology, mechanisms, and management.

Authors:  Absalon D Gutierrez; Ashok Balasubramanyam
Journal:  Endocrine       Date:  2011-12-02       Impact factor: 3.633

5.  Glucagon-like peptide-1 activates endothelial nitric oxide synthase in human umbilical vein endothelial cells.

Authors:  Li Ding; Jin Zhang
Journal:  Acta Pharmacol Sin       Date:  2011-11-28       Impact factor: 6.150

6.  A New Horizon: Oxytocin as a Novel Therapeutic Option for Obesity and Diabetes.

Authors:  Dongsheng Cai; Sudarshana Purkayastha
Journal:  Drug Discov Today Dis Mech       Date:  2013-06-01

7.  Pharmacokinetics and Preliminary Pharmacodynamics of Single- and Multiple-dose Lyophilized Recombinant Glucagon-like Peptide-1 Receptor Agonist (rE-4) in Chinese Patients with Type 2 Diabetes Mellitus.

Authors:  Yitong Wang; Bingfeng Xu; Lixia Zhu; Kun Lou; Yingli Chen; Xia Zhao; Qian Wang; Ling Xu; Xiaohui Guo; Linong Ji; Yimin Cui; Yi Fang
Journal:  Clin Drug Investig       Date:  2017-12       Impact factor: 2.859

8.  Caudal brainstem processing is sufficient for behavioral, sympathetic, and parasympathetic responses driven by peripheral and hindbrain glucagon-like-peptide-1 receptor stimulation.

Authors:  Matthew R Hayes; Karolina P Skibicka; Harvey J Grill
Journal:  Endocrinology       Date:  2008-04-17       Impact factor: 4.736

Review 9.  New drugs for type 2 diabetes mellitus: what is their place in therapy?

Authors:  Andrew J Krentz; Mayank B Patel; Clifford J Bailey
Journal:  Drugs       Date:  2008       Impact factor: 9.546

10.  Hypoglycemic effect of Chlorella vulgaris intake in type 2 diabetic Goto-Kakizaki and normal Wistar rats.

Authors:  Hyejin Jeong; Hye Jin Kwon; Mi Kyung Kim
Journal:  Nutr Res Pract       Date:  2009-03-31       Impact factor: 1.926
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.